NASDAQ:CLNN Clene Q3 2026 Earnings Date & Estimates $4.38 +0.43 (+10.89%) Closing price 11/9/2026 04:00 PM EasternExtended Trading$4.46 +0.08 (+1.83%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Clene is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Clene in Q3 2026Clene is expected to post earnings of -$0.46 per share on revenue of $70 thousand. In the same quarter a year earlier Clene reported -$0.85 per share on revenue of $15 thousand. Clene last reported on November 4, 2026, posting $0.05 per share and beating the -$0.4540 consensus estimate. Clene has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.46Expected Revenue$70 thousandPrior-Year EPS-$0.85Prior-Year Revenue$15 thousandExpected Revenue Growth+366.7%Recent Track RecordLast ReportedQ3 2026Last Quarter EPS$0.05 (Beat by +$0.5040)Last Quarter Revenue$56 thousandEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Q3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Clene Q3 2026 Earnings FAQ When does Clene report Q3 2026 earnings? Clene (NASDAQ:CLNN) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Clene's Q3 2026 earnings call? Clene's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Clene? Analysts expect Clene to post earnings of -$0.46 per share for Q3 2026. How much revenue is Clene expected to report? The consensus revenue estimate for Clene is $70 thousand for Q3 2026. Clene Earnings HeadlinesResearch Analysts Set Expectations for Clene FY2026 EarningsNovember 8 at 1:29 AM | americanbankingnews.comClene (NASDAQ:CLNN) Stock Lifted to Hold by Wall Street ZenNovember 7 at 3:56 AM | americanbankingnews.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 10 at 1:00 AM | Weiss Ratings (Ad)Clene (CLNN) Expected to Announce Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comClene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMClene Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsNovember 4, 2026 | globenewswire.comSee More Clene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clene and other key companies, straight to your email. Email Address About CleneClene (NASDAQ:CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells. Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders. CNM-Au8 remains an investigational therapy and is not approved for general commercial use. Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities primarily through U.S.-based programs, while working with research and clinical collaborators as appropriate. The company is led by Chief Executive Officer Robert Etherington and trades on the Nasdaq under the symbol CLNN.View Clene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength RemainsThe Ugly Truth Behind SoundHound’s Q3 Results Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
